Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081921 | 0.85 | HPGD (0.69) | CYP19A1HPGDHRH4AMY1A | |
| SCHEMBL18080405 | 0.84 | EP300 (0.39) | HPGD | |
| SCHEMBL18080421 | 0.84 | KCNMA1 (0.42) | CYP19A1HPGDHRH4 | |
| SCHEMBL13384415 | 0.84 | HPGD (0.66) | HPGD | |
| SCHEMBL16631451 | 0.84 | CYP19A1 (0.53) | CYP19A1HPGDHRH4AMY1ANPC1 | |
| SCHEMBL18080417 | 0.84 | CA9 (0.50) | AMY1ANPC1 | |
| SCHEMBL18080407 | 0.79 | GRIN1 (0.39) | HPGD | |
| SCHEMBL18080410 | 0.78 | CA9 (0.38) | HPGD | |
| SCHEMBL18080377 | 0.75 | CYP19A1 (0.48) | CYP19A1HRH4AMY1ANPC1RAB9A | |
| SCHEMBL18080418 | 0.75 | EP300 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | CYP19A1 4868/4885HPGD 3931/4885HRH4 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.